Midwest Trust Co Raises Stock Position in IDEXX Laboratories, Inc. $IDXX

Midwest Trust Co lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 28.8% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 17,750 shares of the company’s stock after purchasing an additional 3,969 shares during the quarter. Midwest Trust Co’s holdings in IDEXX Laboratories were worth $12,008,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Virtus Advisers LLC purchased a new stake in IDEXX Laboratories during the 3rd quarter worth approximately $26,000. Park Place Capital Corp purchased a new position in IDEXX Laboratories in the 4th quarter valued at approximately $29,000. WealthCollab LLC purchased a new position in IDEXX Laboratories in the 2nd quarter valued at approximately $30,000. J.Safra Asset Management Corp acquired a new position in shares of IDEXX Laboratories in the third quarter worth $31,000. Finally, Greykasell Wealth Strategies Inc. acquired a new position in shares of IDEXX Laboratories in the third quarter worth $35,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Michael G. Erickson sold 5,371 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total value of $3,369,657.98. Following the completion of the transaction, the executive vice president owned 12,693 shares in the company, valued at approximately $7,963,334.34. This represents a 29.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP George Fennell sold 11,345 shares of the stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the transaction, the executive vice president directly owned 9,823 shares in the company, valued at $6,352,730.56. This trade represents a 53.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 45,957 shares of company stock worth $29,862,109. 0.79% of the stock is owned by insiders.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $560.11 on Monday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. IDEXX Laboratories, Inc. has a fifty-two week low of $487.30 and a fifty-two week high of $769.98. The firm has a market capitalization of $44.18 billion, a PE ratio of 41.25, a price-to-earnings-growth ratio of 3.26 and a beta of 1.58. The stock’s 50-day simple moving average is $585.67 and its 200-day simple moving average is $649.95.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.65 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Piper Sandler reduced their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Citigroup initiated coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price for the company. Barclays reduced their price target on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. BTIG Research decreased their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Finally, Stifel Nicolaus lowered their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.